According to Zhitong Finance App, Via Biotech (01873) issued an announcement. On May 31, 2024, Via Shanghai shareholders have decided to adopt the first phase of the Via Shanghai equity incentive plan and the second phase of the Via Shanghai equity incentive plan. After the relevant approval, the first phase of the Via Shanghai equity incentive plan and the second phase of the Via Shanghai equity incentive plan have each taken effect.

The board of directors recommended the conditional grant of 7.32 million shares of the first instalment stock options to 11 incentive recipients and the conditional grant of 7.32 million share options of the second instalment to 20 incentive recipients in accordance with the relevant plan. We are pleased to announce that due to a number of personnel adjustments made by Via Shanghai Group since the initial announcement was made, 1 grantee of the second instalment stock option (not a group related person) is no longer eligible for incentives. As a result, Via Shanghai has approved the grant of the second instalment of stock options to two eligible grantees under the same terms.

After the revised proposal is granted, a total of 7.32 million first-phase stock options will be awarded to 11 incentive recipients, and a total of 7.32 million second-instalment stock options will be awarded to 21 incentive recipients (not the 20 incentive recipients initially proposed).